OXSI-2

Research use only, not for human use.

OXSI-2 is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM. OXSI-2 completely inhibits Adaptor protein LAT Y191 phosphorylation and Syk mediated events in platelets.

OXSI-2 is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM. OXSI-2 completely inhibits Adaptor protein LAT Y191 phosphorylation and Syk mediated events in platelets.(In Vitro):OXSI-2 (100 nM) does not affect the platelet functional responses induced by Convulxin, and modest shape change is still evident at 1 μM. OXSI-2 (2 μM) completely shape change and blocks GPVI-mediated dense granule release. OXSI-2 (2 μM) inhibits pyroptotic cell death, inflammasome assembly, caspase-1 activation, IL-1β processing and release and mitochondrial ROS generation.

OXSI-2 (2 μM) completely inhibits Convulxin-induced platelet aggregation and shape change. OXSI-2 (2 μM) also completely blocks GPVI-mediated dense granule release. OXSI-2 (100 nM) does not affect the platelet functional responses induced by Convulxin, and modest shape change is still evident at 1 μM.Adaptor protein LAT is a known substrate of Syk Kinase. OXSI-2 completely inhibits LAT Y191 phosphorylation. OXSI-2 inhibits Syk mediated events in platelets.OXSI-2 (2 μM) inhibits inflammasome assembly, caspase-1 activation, IL-1β processing and release, mitochondrial ROS generation, and pyroptotic cell death. Western Blot Analysis Cell Line:Aspirin-treated, washed human platelets Concentration:2 μM Incubation Time:Result:Completely inhibited Syk-mediated LAT Y191 phosphorylation.

——

Syk Inhibitor | OXSI-2 | OXSI2 | OXSI 2

Angiogenesis

Syk

——

——

——

622387-85-3

353.4

C18H15N3O3S

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (28.30 mM)

Cn1cc(\C=C2\C(=O)Nc3ccc(cc23)S(N)(=O)=O)c2ccccc12

——

(-20℃)

With Ice Pack

≥ 2 years